FOLH1 and pachyonychia congenita: Radioligands to the prostate-specific membrane antigen (PSMA) have become the gold standard for the staging of primary prostate cancer (PC) [1–4] and restaging of patients with biochemical recurrence of PC (rPC), outperforming conventional imaging modalities and previous generation radiopharmaceuticals [2].